The Nasdaq listed (IART), Integra Life Sciences Holdings Corp
PNV's main competitor, come on man.
IART has a revenue multiple of x5 with little to no growth profile and its been around for decades.
Come on , me (not x15).
While PNV receives 90% of revenue from the USA, from a product with 90% product margin with high double digit sales growth. The implication of valuing PNV the way you suggest is that DW and the board would consider selling PNV giving zero regard to how the big wide world of finance works. Yeah nah, doubt it, see page 15 Medtech-and-Device-21Q1.pdf (mercercapital.com)
Ann: 1H FY22 Results - Webcast Recording, page-67
-
- There are more pages in this discussion • 181 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PNV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$2.54 |
Change
-0.180(6.62%) |
Mkt cap ! $1.753B | |||
| Open | High | Low | Value | Volume |
| $2.62 | $2.65 | $2.53 | $4.356M | 1.685M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 29641 | $2.53 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.55 | 22158 | 2 |
View Market Depth
| Last trade - 16.10pm 02/08/2024 (20 minute delay) ? |
| PNV (ASX) Chart |